Journal of Jilin University(Medicine Edition) ›› 2021, Vol. 47 ›› Issue (5): 1323-1330.doi: 10.13481/j.1671-587X.20210534
• Review • Previous Articles Next Articles
-
Received:2020-11-02Online:2021-09-28Published:2021-10-26
CLC Number:
- R735
Cite this article
share this article
| 1 | CORLESS C L， HEINRICH M C. Molecular pathobiology of gastrointestinal stromal sarcomas［J］. Annu Rev Pathol， 2008， 3： 557-586. |
| 2 | SCHMIEDER M， HENNE-BRUNS D， MAYER B， et al. Comparison of different risk classification systems in 558 patients with gastrointestinal stromal tumors after R0-resection［J］. Front Pharmacol， 2016， 7： 504. |
| 3 | CAMERON S. Long-term adjuvant treatment of gastrointestinal stromal tumors （GIST） with imatinib-a comment and reflection on the PERSIST-5 study［J］. Transl Gastroenterol Hepatol， 2018， 3： 16. |
| 4 | CHEN T， XU L， YE L， et al. A new nomogram for recurrence-free survival prediction of gastrointestinal stromal tumors： Comparison with current risk classification methods［J］.Eur J Surg Oncol，2019，45（6）：1109-1114. |
| 5 | LIU X， CHU K M. Molecular biomarkers for prognosis of gastrointestinal stromal tumor［J］. Clin Transl Oncol， 2019， 21（2）： 145-151. |
| 6 | GAO Z， WANG C， XUE Q， et al. The cut-off value of tumor size and appropriate timing of follow-up for management of minimal EUS-suspected gastric gastrointestinal stromal tumors［J］. BMC Gastroenterol， 2017， 17（1）： 8. |
| 7 | HU M L， WU K L， CHANGCHIEN C S， et al. Endosonographic surveillance of 1-3 cm gastric submucosal tumors originating from muscularis propria［J］.World J Gastroenterol，2017，23（12）：2194-2200. |
| 8 | WANG M， XUE A， YUAN W， et al. Clinicopathological features and prognosis of small gastric gastrointestinal stromal tumors （GISTs）［J］. J Gastrointest Surg， 2019， 23（11）： 2136-2143. |
| 9 | ZHENG J， LI R， QIU H， et al. Tumor necrosis and >20 mitoses per 50 high-power fields can distinguish ‘very high-risk’ and ‘highest-risk’ within ‘high-risk’ gastric gastrointestinal stromal tumor［J］. Future Oncol， 2018， 14（7）： 621-629. |
| 10 | MIETTINEN M， LASOTA J. Gastrointestinal stromal tumors： pathology and prognosis at different sites［J］. Semin Diagn Pathol， 2006， 23（2）： 70-83. |
| 11 | CORLESS C L， BALLMAN K V， ANTONESCU C R，et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor： the ACOSOG Z9001 trial［J］. J Clin Oncol， 2014， 32（15）： 1563-1570. |
| 12 | JOENSUU H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor［J］. Hum Pathol， 2008， 39（10）： 1411-1419. |
| 13 | CASALI P G， ABECASSIS N， ARO H T， et al. Gastrointestinal stromal tumours： ESMO-EURACAN Clinical Practice Guidelines for diagnosis， treatment and follow-up［J］. Ann Oncol， 2018， 29（）：iv68-iv78. |
| 14 | NISHIDA T， HØLMEBAKK T， RAUT C P， et al. Defining tumor rupture in gastrointestinal stromal tumor［J］. Ann Surg Oncol， 2019， 26（6）： 1669-1675. |
| 15 | HØLMEBAKK T， HOMPLAND I， BJERKEHAGEN B，et al. Recurrence-free survival after resection of gastric gastrointestinal stromal tumors classified according to a strict definition of tumor rupture： a population-based study［J］. Ann Surg Oncol， 2018， 25（5）： 1133-1139. |
| 16 | YANG D Y， WANG X， YUAN W J， et al. Metastatic pattern and prognosis of gastrointestinal stromal tumor （GIST）：a SEER-based analysis［J］. Clin Transl Oncol， 2019， 21（12）： 1654-1662. |
| 17 | HOMPLAND I， BRULAND Ø S， HØLMEBAKK T， et al. Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor： analysis of a large， single-institution cohort［J］.Acta Oncol，2017，56（10）：1317-1323. |
| 18 | SATO S， TSUJINAKA T， MASUZAWA T， et al. Role of metastasectomy for recurrent/metastatic gastrointestinal stromal tumors based on an analysis of the Kinki GIST registry［J］. Surg Today， 2017， 47（1）： 58-64. |
| 19 | CAI Z， YIN Y， SHEN C， et al. Role of surgical resection for patients with recurrent or metastatic gastrointestinal stromal tumors： a systematic review and meta-analysis［J］. Int J Surg， 2018， 56： 108-114. |
| 20 | SCHRAGE Y， HARTGRINK H， SMITH M， et al. Surgical management of metastatic gastrointestinal stromal tumour［J］. Eur J Surg Oncol， 2018， 44（9）： 1295-1300. |
| 21 | BAUER S， RUTKOWSKI P， HOHENBERGER P， et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib： analysis of prognostic factors （EORTC-STBSG collaborative study）［J］.Eur J Surg Oncol，2014，40（4）：412-419. |
| 22 | SHANNON A B， SONG Y， FRAKER D L， et al. Do microscopic surgical margins matter for primary gastric gastrointestinal stromal tumor？ ［J］. Surgery， 2021， 169（2）： 419-425. |
| 23 | HØLMEBAKK T， BJERKEHAGEN B， HOMPLAND I， et al. Relationship between R1 resection， tumour rupture and recurrence in resected gastrointestinal stromal tumour［J］. Br J Surg， 2019， 106（4）： 419-426. |
| 24 | PANTUSO G， MACAIONE I， TAVERNA A， et al. Surgical treatment of primary gastrointestinal stromal tumors （GISTs）：Management and prognostic role of R1 resections［J］. Am J Surg， 2020， 220（2）： 359-364. |
| 25 | GRONCHI A， BONVALOT S， POVEDA VELASCO A， et al. Quality of surgery and outcome in localized gastrointestinal stromal tumors treated within an international intergroup randomized clinical trial of adjuvant imatinib［J］.JAMA Surg，2020，155（6）： e200397. |
| 26 | CORLESS C L， BARNETT C M， HEINRICH M C. Gastrointestinal stromal tumours： origin and molecular oncology［J］. Nat Rev Cancer， 2011， 11（12）： 865-878. |
| 27 | ZONG L， CHEN P. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors： a meta-analysis［J］. World J Surg Oncol， 2014， 12： 71. |
| 28 | LASOTA J， DANSONKA-MIESZKOWSKA A， SOBIN L H， et al. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential［J］. Lab Invest， 2004， 84（7）： 874-883. |
| 29 | ROSSI S， GASPAROTTO D， MICELI R， et al. KIT， PDGFRA， and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST： a population-based study［J］. Am J Surg Pathol， 2015， 39（7）： 922-930. |
| 30 | SZUCS Z， THWAY K， FISHER C， et al. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications［J］. Future Oncol， 2017， 13（1）： 93-107. |
| 31 | WOZNIAK A， RUTKOWSKI P， PISKORZ A， et al. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours （GIST）：Polish Clinical GIST Registry experience［J］.Ann Oncol， 2012，23（2）： 353-360. |
| 32 | JOENSUU H， RUTKOWSKI P， NISHIDA T， et al. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence［J］. J Clin Oncol， 2015， 33（6）： 634-642. |
| 33 | DEMETRI G D， WANG Y F， WEHRLE E， et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors［J］. J Clin Oncol， 2009， 27（19）： 3141-3147. |
| 34 | QIAN Y， SUN L N， LIU Y J， et al. Genetic polymorphisms and adverse events on unbound imatinib and its active metabolite concentration in patients with gastrointestinal stromal tumors［J］. Front Pharmacol， 2019， 10： 854. |
| 35 | VERBOOM M C， KLOTH J S L， SWEN J J， et al. Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors［J］. Pharmacogenomics J， 2019， 19（5）： 473-479. |
| 36 | KOO D H， RYU M H， RYOO B Y， et al. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor［J］. Cancer Chemother Pharmacol， 2015，75（1）： 173-182. |
| 37 | ANGELINI S， PANTALEO M A， RAVEGNINI G， et al. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy［J］. Pharmacol Res， 2013， 68（1）： 1-6. |
| 38 | VERBOOM M C， KLOTH J S L， SWEN J J， et al. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib［J］. Eur J Cancer， 2017， 86： 226-232. |
| 39 | BRAHMI M， ALBERTI L， DUFRESNE A， et al. KIT exon 10 variant （c.1621 A>C） single nucleotide polymorphism as predictor of GIST patient outcome［J］. BMC Cancer， 2015， 15（1）： 1-8. |
| 40 | ANGELINI S， RAVEGNINI G， NANNINI M， et al. Folate-related polymorphisms in gastrointestinal stromal tumours： susceptibility and correlation with tumour characteristics and clinical outcome［J］. Eur J Hum Genet， 2015， 23（6）： 817-823. |
| 41 | GEDDERT H， BRAUN A， KAYSER C， et al. Epigenetic regulation of CD133 in gastrointestinal stromal tumors［J］. Am J Clin Pathol， 2017， 147（5）： 515-524. |
| 42 | HALLER F， ZHANG J D， MOSKALEV E A， et al. Combined DNA methylation and gene expression profiling in gastrointestinal stromal tumors reveals hypomethylation of SPP1 as an independent prognostic factor［J］. Int J Cancer， 2015， 136（5）： 1013-1023. |
| 43 | NIINUMA T， KAI M， KITAJIMA H， et al. Downregulation of miR-186 is associated with metastatic recurrence of gastrointestinal stromal tumors［J］. Oncol Lett， 2017， 14（5）： 5703-5710. |
| 44 | WANG Y， LI J， KUANG D， et al. miR-148b-3p functions as a tumor suppressor in GISTs by directly targeting KIT［J］.Cell Commun Signal，2018，16（1）： 16. |
| 45 | LONG Z W， WU J H， CAI-HONG， et al. MiR-374b promotes proliferation and inhibits apoptosis of human GIST cells by inhibiting PTEN through activation of the PI3K/Akt pathway［J］.Mol Cells，2018，41（6）： 532-544. |
| 46 | LIU X， QIU H， ZHANG P， et al. Ki-67 labeling index may be a promising indicator to identify “very high-risk” gastrointestinal stromal tumor： a multicenter retrospective study of 1022 patients［J］. Hum Pathol， 2018， 74： 17-24. |
| 47 | ZHAO W Y， XU J， WANG M， et al. Prognostic value of Ki67 index in gastrointestinal stromal tumors［J］. Int J Clin Exp Pathol， 2014， 7（5）： 2298-2304. |
| 48 | MARTINHO O， GOUVEIA A， SILVA P， et al. Loss of RKIP expression is associated with poor survival in GISTs［J］. Virchows Arch， 2009， 455（3）： 277-284. |
| 49 | WANG Y， CHEN J J， WANG X F， et al. Clinical and prognostic significance of Raf kinase inhibitory protein expression in gastrointestinal stromal tumors［J］. World J Gastroenterol， 2018， 24（23）： 2508-2517. |
| 50 | WANG J L， WU J H， HONG C， et al. Involvement of Bmi-1 gene in the development of gastrointestinal stromal tumor by regulating p16Ink4A/p14ARF gene expressions： an in vivo and in vitro study［J］. Pathol Res Pract， 2017， 213（12）： 1542-1551. |
| 51 | ZHU K， LI K， YUAN D W， et al. Clinicopathological and prognostic significance of expression of B-cell-specific moloney murine leukemia virus insertion site 1 （BMI-1） gene and protein in gastrointestinal stromal tumors［J］. Med Sci Monit， 2018， 24： 6414-6421. |
| 52 | RIZZO F M， PALMIROTTA R， MARZULLO A，et al.Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations［J］. BMC Cancer， 2016， 16： 87. |
| 53 | LI Q， ZHI X， ZHOU J， et al. Circulating tumor cells as a prognostic and predictive marker in gastrointestinal stromal tumors： a prospective study［J］. Oncotarget， 2016， 7（24）： 36645-36654. |
| 54 | JUNG S H， SUH K S， KANG D Y， et al. Expression of DOG1， PDGFRA， and p16 in gastrointestinal stromal tumors［J］. Gut Liver， 2011， 5（2）： 171-180. |
| [1] | Gengfei CAO, SHAYA·Mahati,Junpeng GU,Weizheng JI, ASIHAER·Hasimu,Weixin REN. Differences in immune microenvironment between DEB-TACE and c-TACE in treatment of hepatocellular carcinoma and mechanism of TRADD-mediated Th17 differentiation [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 764-780. |
| [2] | Wei ZHOU,Yangyang HE,Youde WANG,Wenzhuo MA,Heng KANG. Effect of histone deacetylase 6 inhibitor ACY-241 on macrophage polarization and biological behaviors of esophageal cancer cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 621-632. |
| [3] | Yu ZHAO,Xiaoshuang HE,Xiaoyin DONG,Fengyi GAO,Jiageng HE. Regulatory effect of lncRNA urothelial carcinoembryonic antigen 1 on anoikis in human gastrointestinal stromal tumor cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2026, 52(2): 429-439. |
| [4] | Zhongwei ZHOU,Wei DU,Yu NING,Jing YU,Fengyou GUO,Xueliang YANG. SMARCB1/INI1-deficient undifferentiated pancreatic carcinoma: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2026, 52(2): 523-529. |
| [5] | Jiaxin WANG,Junwen MAO,Xuan ZHANG. Expression of natural autoantibodies against apoptosis inhibitory genes in plasma of patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 228-235. |
| [6] | Renyi YANG,Jincheng TANG,Kexiong LI,Wei PENG,Zhuo LIU,Ling WU,Puhua ZENG. Temporal trends and attributable risk analysis of liver cancer burden in China from 1990 to 2021 [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 199-210. |
| [7] | Yuxin LI,Lu YANG,Fengjin LI,Ling QI. Inductive effect of wedelolactone on cuproptosis in human pancreatic cancer PANC-1 cells [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 182-191. |
| [8] | Dayou DAI,Zhigang ZHANG,Hui LI. Effect of CHRNA5 in occurrence and development of pancreas cancer and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1518-1531. |
| [9] | Limei WEN,Yali GUO,Wenmei MA,Taotao XUE,Ruoyu GENG,Chong MA,Xinhong ZHANG,Jianhua YANG. Bioinformatic analysis of TCGA database based on INPP4B gene expression in hepatocellular carcinoma and its experimental validation [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1618-1629. |
| [10] | Fei WU,Qiwei YANG,Xin LI,Linxian ZHAO,Yujie SUI. Expressions of ANO1 and E-cadherin in human primary colorectal cancer tissue and their significances [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1638-1645. |
| [11] | Pingsheng ZHU,Sitang GE,Lugen ZUO,Deli CHEN,Yangyang ZHANG. Effect of miR-325-3p targeting PRELID1 gene in regulation of EMT pathway on invasion and migration of colon cancer cells and their mechanisms [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1185-1193. |
| [12] | Hongli LI,Mengyao WANG,Yangyang LIU,Hui ZHANG,Li LI. Effect of KHSRP on biological behavior of colorectal cancer cells through activation of JAK/STAT signaling pathway [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 996-1006. |
| [13] | Huixian XU,Hui XU,Jishu QUAN,Feng ZHENG. Inhibitory effect of iridoid glycosides from Boschniakia rossica on hepatic preneolasia of rats and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 887-895. |
| [14] | Xianlei ZHOU,Zimo YAN,Liwen GUO,Xuemei ZHANG. Mendelian randomization analysis based on causal association of sterol esters with occurrence of intrahepatic ductal, biliary, and gallbladder malignancy [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 1084-1093. |
| [15] | Ziru ZHOU,Mengfei SUN,Huakun ZHANG,Shuyan SUN,Qi SUN,Feng LI,Yunzhao CHEN,Jie YU,Yuwen CAO,Xiaobin CUI. Expression of Rh family C glycoprotein in esophageal squamous carcinoma and its clinical significance [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 1019-1027. |